6-Methyl-1-(oxan-4-yl)benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 6-Methyl-1-(oxan-4-yl)benzimidazole
• 英文别名: 6-methyl-1-(oxan-4-yl)benzimidazole
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.28
• InChiKey: FNMMPTFNWXUDNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100695A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20150133427A1

  公开（公告）日：2015-05-14

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐和药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10023576B2

  公开（公告）日：2018-07-17

  Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

  公开了式(I)化合物；或其盐；其中Qi是(i)Cl、Br、I、-CN、-CH3或-CF3；或(ii)吡唑、三唑或吡啶基，各自被R1取代；Q2是吡啶基、吲唑基、异喹啉基或被R2和R3取代的苯并[d]咪唑基；R1、R2和R3在本文中定义。还公开了使用此类化合物作为 PI3K 调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓炎症性和自身免疫性疾病。
• SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3209665B1

  公开（公告）日：2019-08-14
• HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170355698A1

  公开（公告）日：2017-12-14

  Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH 3 , or —CF 3 ; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R 1 ; Q 2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R 2 and R 3 ; and R 1 , R 2 , and R 3 are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.